Monograph: Optimizing Outcomes in COPD: Addressing Current Challenges and Overcoming Barriers
This JAAPA supplement monograph outlines current guidelines, management and treatment for patients with COPD. Also available, eCase Challenge 1 and eCase Challenge 2: Optimizing Outcomes in COPD: Addressing Current Challenges and Overcoming Barriers

Monograph: Optimizing Outcomes in COPD: Addressing Current Challenges and Overcoming Barriers

Lawrence Herman, MPA, PA-C, DFAAPA; Christy P. Wilson, MPAS, PA-C

COPD is a progressive, yet treatable, disease that is a leading cause of morbidity and mortality across the globe. While its progression varies widely between cases, clinical exacerbations and comorbidities contribute to the degree of symptom severity observed on an individual basis. The clinical manifestations of COPD place a considerable burden on the healthcare system and negatively impact patient morbidity, mortality and quality of life, often with exacerbations that affect daily function for weeks at a time. A significant proportion of patients with the disease remain undiagnosed and under-treated, partly because of the symptomatic overlap with other conditions. As such, COPD is a difficult disease to manage and its complexity, both in diagnosis and pharmacologic therapies, is challenging for those in the primary care setting. Continuing educational directives should have the goals of facilitating the early and accurate diagnosis of COPD and outlining appropriate therapeutic regimens for both stable disease and exacerbations in order to improve symptom management and patient quality of life.

Educational Objectives

At the conclusion of this activity, the PA should be better able to:
  • Use the diagnosis and grading recommendations provided by the GOLD guidelines.
  • Summarize currently approved formulations of COPD medications and regimens that are appropriate for various grades of COPD.
  • Discuss COPD medications currently in clinical development.
  • Outline the pharmacological therapies available for the management of COPD exacerbations.

Accreditation Statement

This activity has been reviewed and is approved for a maximum of 1.50 AAPA Category 1 CME credit by the AAPA Review Panel. Participants should only claim credit commensurate with their participation in the CME activity. This program was planned in accordance with AAPA’s CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs. Approval is valid until December 31, 2018.

Responsibility Statement

AAPA takes responsibility for the content, quality, and scientific integrity of this CME activity.

Disclosure Policy Statement

It is the policy of AAPA to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member has with the commercial interest of any commercial product discussed in an educational presentation. The participating faculty reported the following:

Faculty

Lawrence Herman, MPA, PA-C, DFAAPA
Retired Professor and Dean Emeritus
College of Health Sciences
PA Studies
Gardner-Webb University
Boiling Springs, NC
Consultant: Novo Nordisk
Speaker's Bureau: Novo Nordisk

Christy P. Wilson, MPAS, PA-C
Pulmonary and Sleep Medicine APP Director
Piedmont Pulmonary Division
Piedmont Physicians Georgia Lung Associates
Atlanta, GA
No relationship with any commercial interests whose products or services may be mentioned during this presentation.

Activity Planners

Michael Speidel, Jennifer Gregg, PhD and Joanne Jeffers, Medical Logix, LLC have no relationship with any commercial interests whose products or services may be mentioned during this presentation.

AAPA Staff Activity Planners

Daniel Pace and Jennifer Williams have no relationship with any commercial interests whose products or services may be mentioned during this presentation.

Off-Label/Unapproved Product(s) Discussion

Benralizumab, fluticasone furoate/umeclidinium/vilanterol, glycopyrrolate/formoterol, mepolizumab, revefenacin.

Disclaimer

The opinions and comments expressed by faculty and other experts, whose input is included in this program, are their own. This enduring material is produced for educational purposes only. Please review complete prescribing information of specific drugs mentioned in this program including indications, contraindications, warnings, and adverse effects and dosage before administering to patients.

Acknowledgement of Commercial Support

Jointly supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., Mylan Specialty L.P., and GlaxoSmithKline.

AAPA offers no returns or refunds for online CME activities purchased through the AAPA store. All sales are final.


Type:     Internet Activity (Enduring Material)
1246 Registered Users